Institutional investors are piling into pharmaceutical stocks, offering clear signals on where smart money is heading. Rising buying activity from domestic and foreign funds reflects growing confidence in the sector's earnings trajectory, pipeline launches, and long-term expansion.
Today, we look at four pharma stocks that have seen institutional buying. However, investors should check each company’s performance, valuations and risks before making any investment decisions.
Gujarat Themis Biosyn (GTBL) was incorporated in 1981 as a joint-sector company with Gujarat Industrial Investment Corporation (GIIC) Limited.
It commenced operations by producing the antibiotic erythromycin and its salts. In 1991, Chemosyn Pvt. Ltd. transferred ownership of the company to Pharmaceutical Business Group (India) Ltd. (PBG).
Subsequently, Themis Medicare and PBG entered into a technical and financial collaboration with Yuhan Corporation, South Korea. With Yuhan Corporation’s technical expertise, GTBL became the first company in India to begin commercial production and marketing of rifampicin, an anti-tuberculosis medicine.